Del Toro G, Satwani P, Harrison L, Cheung Y-K, Brigid Bradley M, George D, Yamashiro D J, Garvin J, Skerrett D, Bessmertny O, Wolownik K, Wischhover C, van de Ven C, Cairo M S
Department of Pediatrics, Children's Hospital New York-Presbyterian, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA.
Bone Marrow Transplant. 2004 Mar;33(6):613-22. doi: 10.1038/sj.bmt.1704399.
Reduced intensity (RI) allogeneic stem cell transplantation (AlloSCT) was initially demonstrated in adults following HLA-matched family and unrelated adult donor AlloSCT. There is little information about RI AlloSCT in children. We report results of a pilot study of RI AlloSCT in 21 recipients (< or =21 years). Age: median 13 (0.5-21) years, 8F:13M, 14 unrelated cord blood units (UCB) (10 4/6, 4 5/6), two related BM (6/6, 5/6), four related PBSC (2 6/6, 2 5/6), and one related BM+PBSC (6/6). RI: fludarabine, busulfan (n=14); fludarabine, cyclophosphamide (n=4); fludarabine, melphalan (n=1); total body irradiation, fludarabine, cyclophosphamide (n=1); or fludarabine, cyclophosphamide, and etoposide (n=1). Graft-versus-host disease prophylaxis: FK506 0.03 mg/kg/day and mycophenolate mofetil 15 mg/kg/q 12 h. UCB median nuc/kg and CD34/kg was 4.3 x 10(7)/kg (0.9-10.8) and 1.9 x 10(5)/kg (0.3-6.9), and related BM/PBSC median nuc/kg and CD34/kg was 8.3 x 10(8) (4.7-18.9) and 5.0 x 10(6)/kg (4.6-6.4). Maximal chimerism following unrelated cord blood transplantation, 100% x 7, 98% x 1, 95% x 2, 55% x 1, and 0% x 3; related PBSC/BM, 100% x 5, 65% x 1, and 55% x 1. Graft failure occurred in 5/21 (24%). In summary, RI AlloSCT in children is feasible and tolerable (< or =25% GF) and results in > or =85% of recipients initially achieving > or =50% donor chimerism.
降低强度(RI)异基因干细胞移植(AlloSCT)最初是在 HLA 匹配的家族和无关成人供体 AlloSCT 后的成人中得到证实。关于儿童 RI AlloSCT 的信息很少。我们报告了一项针对 21 名受体(≤21 岁)的 RI AlloSCT 试点研究结果。年龄:中位数 13(0.5 - 21)岁,8 名女性:13 名男性,14 个无关脐血单位(UCB)(10 个 4/6,4 个 5/6),2 个相关骨髓(6/6,5/6),4 个相关外周血干细胞(2 个 6/6,2 个 5/6),以及 1 个相关骨髓 + 外周血干细胞(6/6)。RI 方案:氟达拉滨、白消安(n = 14);氟达拉滨、环磷酰胺(n = 4);氟达拉滨、美法仑(n = 1);全身照射、氟达拉滨、环磷酰胺(n = 1);或氟达拉滨、环磷酰胺和依托泊苷(n = 1)。移植物抗宿主病预防:FK506 0.03 mg/kg/天和霉酚酸酯 15 mg/kg/每 12 小时。UCB 的中位有核细胞数/kg 和 CD34 细胞数/kg 分别为 4.3×10⁷/kg(0.9 - 10.8)和 1.9×10⁵/kg(0.3 - 6.9),相关骨髓/外周血干细胞的中位有核细胞数/kg 和 CD34 细胞数/kg 分别为 8.3×10⁸(4.7 - 18.9)和 5.0×10⁶/kg(4.6 - 6.4)。无关脐血移植后的最大嵌合率,100%×7,98%×1,95%×2,55%×1,0%×3;相关外周血干细胞/骨髓,100%×5,65%×1,55%×1。5/21(24%)发生移植物失败。总之,儿童 RI AlloSCT 是可行且可耐受的(≤25%移植物失败),并且≥85%的受体最初实现≥50%的供体嵌合率。